Multiple sclerosis and related disorders · 2026
Real-world transition from uncontrolled disease to stability: Three-year Pre-post natalizumab comparison in relapsing multiple sclerosis.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ozakbas Serkan, Mammadov Orkhan, Alizada Said, Samadzade Ulvi, Caliskan Can, Simsek Yasemin
Аннотация
BACKGROUND: Natalizumab is a highly effective therapy for relapsing multiple sclerosis (MS), yet few real-world studies have directly compared disease activity before and after treatment initiation within the same patients.
OBJECTIVE: To evaluate the real-world impact of natalizumab on relapse activity, disability, and MRI activity by comparing disease outcomes during the three years before and after treatment initiation.
METHODS: We retrospectively analyzed 246 patients who initiated natalizumab at a single centre. After excluding patients without baseline data (n = 38) or with insufficient follow-up or incomplete MRI data (n = 77), 131 patients were included in the final analysis. Annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS), and MRI activity were compared between the 36-month pre-treatment and 36-month on-treatment periods.
RESULTS: Natalizumab treatment was associated with a marked reduction in relapse activity. Mean ARR decreased from 0.69 in the pre-treatment period to 0.04 during the on-treatment period, and the proportion of patients with relapses declined from 88.5% to 8.4%. Disability remained overall stable during follow-up, with no significant difference between EDSS three years before treatment and EDSS three years after treatment. MRI activity decreased from 74.8% in the pre-treatment period to 9.2% during the on-treatment period, and 84.0% of patients achieved no evidence of disease activity (NEDA-3). Pregnancy-related observations were limited to a small descriptive subgroup.
CONCLUSION: Over three years, natalizumab was associated with substantial suppression of relapse activity, stable disability, and reduced MRI activity compared with the pre-treatment period.
OBJECTIVE: To evaluate the real-world impact of natalizumab on relapse activity, disability, and MRI activity by comparing disease outcomes during the three years before and after treatment initiation.
METHODS: We retrospectively analyzed 246 patients who initiated natalizumab at a single centre. After excluding patients without baseline data (n = 38) or with insufficient follow-up or incomplete MRI data (n = 77), 131 patients were included in the final analysis. Annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS), and MRI activity were compared between the 36-month pre-treatment and 36-month on-treatment periods.
RESULTS: Natalizumab treatment was associated with a marked reduction in relapse activity. Mean ARR decreased from 0.69 in the pre-treatment period to 0.04 during the on-treatment period, and the proportion of patients with relapses declined from 88.5% to 8.4%. Disability remained overall stable during follow-up, with no significant difference between EDSS three years before treatment and EDSS three years after treatment. MRI activity decreased from 74.8% in the pre-treatment period to 9.2% during the on-treatment period, and 84.0% of patients achieved no evidence of disease activity (NEDA-3). Pregnancy-related observations were limited to a small descriptive subgroup.
CONCLUSION: Over three years, natalizumab was associated with substantial suppression of relapse activity, stable disability, and reduced MRI activity compared with the pre-treatment period.